methyl 2-(tetrahydropyran-2-yloxy)hexanoate | 118565-80-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl 2-(tetrahydropyran-2-yloxy)hexanoate
• 英文别名: Methyl 2-(2-Tetrahydropyranyl)oxycaproate；methyl 2-(tetrahydro-2H-pyran-2-yloxy)hexanoate；methyl 2-(oxan-2-yloxy)hexanoate
• CAS: 118565-80-3
• 化学式: C₁₂H₂₂O₄
• 分子量: 230.304
• InChiKey: XBJUIJQICLRPKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 2-(tetrahydropyran-2-yloxy)hexanoate 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 0.33h， 生成 2-(tetrahydropyran-2-yloxy)hexan-1-ol
  参考文献：
  名称：

  High diastereoselection in the aldol reaction of the bistrimethylsilyl enol ether of methyl acetoacetate with 2-benzyloxyhexanal: synthesis of (–)-pestalotin

  摘要：

  Aldol condensation of the bistrimethylsilyl enol ether of methyl acetoacetate, compound 2, with 2-benzyloxyhexanal 3c affords highly selectively (99:1) the syn-aldol adduct 4c in the presence of titanium tetrachloride. The stereocontrolled synthesis of (-)-pestalotin 7 has been achieved.

  DOI：

  10.1039/p19920000693
• 作为产物：
  描述：

  DL-Alpha-羟基己酸 在 4-甲基苯磺酸吡啶 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 19.17h， 生成 methyl 2-(tetrahydropyran-2-yloxy)hexanoate
  参考文献：
  名称：

  High diastereoselection in the aldol reaction of the bistrimethylsilyl enol ether of methyl acetoacetate with 2-benzyloxyhexanal: synthesis of (–)-pestalotin

  摘要：

  Aldol condensation of the bistrimethylsilyl enol ether of methyl acetoacetate, compound 2, with 2-benzyloxyhexanal 3c affords highly selectively (99:1) the syn-aldol adduct 4c in the presence of titanium tetrachloride. The stereocontrolled synthesis of (-)-pestalotin 7 has been achieved.

  DOI：

  10.1039/p19920000693

文献信息

• Prostaglandins E and anti-ulcers containing same
  申请人：K.K. Ueno Seiyaku Oyo Kenkyujo

  公开号：US05166174A1

  公开（公告）日：1992-11-24

  The novel 13,14-dihydro-15-keto prostaglandins E of the invention have remarkable preventive effects against ulcers. Further, the novel 13,14-dihydro-15-keto-prostaglandins E of the invention have an advantage that they have none of side effects which prostaglandin E intrinsically has, or can remarakably reduce such effects of the prostaglandin E. Therefore, the novel 13,14-dihydro-15-keto prostaglandins E of the invention are effective for animal and human use for treatment and prevention of ulcers, such as duodenal ulcer and gastric ulcer.

  这项发明的新型13,14-二氢-15-酮前列腺素E具有显著的预防溃疡作用。此外，这项发明的新型13,14-二氢-15-酮前列腺素E具有一个优势，即它们没有前列腺素E固有的任何副作用，或者可以显著减少前列腺素E的这些副作用。因此，这项发明的新型13,14-二氢-15-酮前列腺素E对于动物和人类用于治疗和预防溃疡，如十二指肠溃疡和胃溃疡，具有有效性。
• PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS
  申请人：Barta Nancy S.

  公开号：US20090124695A1

  公开（公告）日：2009-05-14

  A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions.

  一种选择性作用于EP受体的前列腺素类似物，表现出EP激动剂活性，可用于扩大造血干细胞群体或用于治疗或预防流感、骨折、骨病、青光眼、眼压升高、痛经、早产、免疫紊乱、骨质疏松症、哮喘、过敏、男性性功能障碍、女性性功能障碍、牙周病、胃溃疡、肾脏疾病或其他EP受体介导的疾病。
• Prostaglandins E and anti ulcers containing same
  申请人：Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo

  公开号：EP0284180B1

  公开（公告）日：1992-08-19
• SAJTO, SINITI;INOUEH, XIROMITI;MIYADZAVA, KADZUTOSI;ONO, KODZI;USIODA, MA+
  作者：SAJTO, SINITI、INOUEH, XIROMITI、MIYADZAVA, KADZUTOSI、ONO, KODZI、USIODA, MA+

  DOI：——

  日期：——
• US5166174A
  申请人：——

  公开号：US5166174A

  公开（公告）日：1992-11-24